3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
3
Phase 1
2
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
151
Lung Neoplasms
34
Carcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Neoplasms
9
Neoplasm Metastasis
9
Mesothelioma
5
Adenocarcinoma of Lung
5
Uterine Cervical Neoplasms
4
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Mesothelioma, Malignant
4
Lung Diseases
4
Carcinoma, Bronchogenic
4
Non-squamous Non-small Cell Lung Cancer
3
Non-Squamous Non-Small Cell Lung Cancer
3
Neoplasms by Site
3
NSCLC
3
Bronchial Neoplasms
3
Adenocarcinoma
3
Recurrence
2
Non-Squamous Non-small Cell Lung Cancer
2
Non Small Cell Lung Carcinoma NSCLC
2
Head and Neck Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
Gemcitabine
12
Mitomycin
11
Cisplatin
10
Carboplatin
8
pembrolizumab
7
Docetaxel
4
toripalimab
3
avelumab
3
atezolizumab
3
Paclitaxel
3
sacituzumab govitecan
2
disitamab vedotin
2
Taxes
2
Specimen Handling
2
Platinum
2
Magnetic Resonance Spectroscopy
2
Injections
2
1,2-diaminocyclohexaneplatinum II citrate
2
vinflunine
1
valrubicin
1
tislelizumab
1
lenvatinib
1
eribulin
1
epacadostat
1
enfortumab vedotin
1
durvalumab
1
dodecyl maltoside
1
Vitamin B 12
1
Standard of Care
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Transitional Cell
×
Pemetrexed
×
Clear all
NCT03193788
2017-06-21
PREMIER
Asan Medical Center
Phase 3
Unknown
74 enrolled